BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie

BioNTech and Bristol Myers Squibb announced positive Phase 2 results from the ROSETTA Lung-107 trial showing Pumitamig (BNT327/BMS986545) in combination with Docetaxel achieved a 36.7% objective response rate and 6.9-month median progression-free survival in patients with metastatic non-small cell lung cancer that progressed after first-line immunotherapy plus chemotherapy. The drug demonstrated a manageable safety profile with consistent activity across PD-L1 expression levels and histological subtypes.